After five years of unprecedented momentum, the ADC field now finds itself at an interesting inflection point. With more programs in development and greater industry prioritization than ever before, ...
AbbVie has claimed its first regulatory approval, from the FDA, for its C-met-targeting antibody-drug conjugate (ADC) Emrelis as a treatment for a type of lung cancer. The US regulator cleared Emrelis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results